Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$0.30
EPS est.
$0.62
EPS surprise
-51.46%
1-day move
-2.21%
TransMedics Group, Inc. reported earnings that fell short of expectations, particularly in EPS, which may raise concerns among investors. Despite the miss, the stock reaction was flat, indicating that investors may have anticipated the results. Without any guidance or commentary from management, the outlook remains uncertain.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.30 | $0.61 | -51.46% |
| Revenue | — | $174M | — |
No transcript is on record, and the analysis is based on numerical results only.
TransMedics Group, Inc. is a healthcare company focused on innovative organ transplant solutions. Their technology aims to improve the success rates of organ transplants, which is crucial as demand for organ donations continues to rise. With a market cap of $3 billion, they operate in the health care equipment sector, addressing a significant need in patient care.
Last quarter
In the last quarter, TransMedics reported an impressive EPS of $2.62, significantly exceeding expectations. The stock reacted positively, gaining 2.32% the following day.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
63%
Avg EPS surprise
+92.10%
Avg 1-day reaction
+0.17%
Analysts are generally optimistic about TransMedics' upcoming earnings, expecting solid growth in both EPS and revenue. The company has a strong track record of beating earnings estimates, which adds to positive sentiment.
Bull case
If TransMedics can deliver an EPS above the consensus and show strong revenue growth, it may reinforce investor confidence and drive the stock higher.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the high implied volatility.
Key metrics to watch
EPS
$0.61Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs and revenues.
Revenue
$174MTotal revenue reflects the company's ability to generate sales and is critical for assessing growth potential.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $0.61?
A beat on EPS could signal strong operational performance and boost investor confidence.
Q2
What guidance will management provide regarding revenue growth?
Clear guidance on revenue growth will help investors gauge the company's future prospects and market position.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate the potential for revenue growth due to new product launches and market expansion strategies that have not been fully accounted for.
Supporting evidence
The company has consistently beaten EPS estimates, indicating stronger performance than expected.
Recent trends in organ transplant demand suggest a growing market that could drive revenue higher than consensus estimates.
Key risk
If the company announces a significant new partnership or product that enhances revenue potential, it could shift market expectations dramatically.
Pre-commit to what would confirm each case.
The market is debating whether TransMedics can sustain its recent growth trajectory, especially after a series of strong earnings surprises.
Bull confirmed if
An EPS of $0.70 or higher would confirm the bull case, indicating strong demand for their products.
Bear confirmed if
An EPS below $0.45 would confirm the bear case, suggesting potential issues in sales or cost management.
What the market is pricing for the move.
Implied Move
±15.52%
Historical Avg
±2.2%
The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings report.
Options are pricing ±15.5% while TMDX has averaged ±2.2% over the last 8 prints — setup is pricing rich.
ATM IV
1.1%
30d HV
53.7%
Smart-money positioning from the most recent 13F filings.
Institutional
103.01%
of float
Insider
3.64%
of float
Holders
489
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
5,596,549 sh · $453.7M
16.19%
5.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If TransMedics beats expectations, history suggests the stock could rise by around 0.46%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.
Miss
Should the company miss expectations, the stock could decline by approximately 0.85%, reflecting disappointment among investors.
The lines on the call that would change the story.
FMR, LLC
5,133,328 sh · $416.2M
14.85%
0.7%
Vanguard Portfolio Management LLC
1,933,989 sh · $156.8M
5.60%
0.8%
Vanguard Capital Management LLC
1,497,600 sh · $121.4M
4.33%
1.3%
State Street Corporation
1,420,421 sh · $115.2M
4.11%
7.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.